Olivier L Chinot
Overview
Explore the profile of Olivier L Chinot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esparragosa Vazquez I, Sanson M, Chinot O, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, et al.
Neurooncol Adv
. 2024 Jun;
6(1):vdae078.
PMID: 38855053
Background: Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy...
2.
Le Rhun E, Gorlia T, Felsberg J, Jongen J, Maurage C, Ducray F, et al.
Eur J Cancer
. 2024 Apr;
204:114066.
PMID: 38658199
No abstract available.
3.
Le Rhun E, Gorlia T, Felsberg J, Jongen J, Maurage C, Ducray F, et al.
Eur J Cancer
. 2023 Dec;
198:113475.
PMID: 38159337
Background: Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently...
4.
Draaisma K, Tesileanu C, de Heer I, Klein M, Smits M, Reijneveld J, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2440-2448.
PMID: 35294545
Purpose: Despite recent advances in the molecular characterization of gliomas, it remains unclear which patients benefit most from which second-line treatments. The TAVAREC trial was a randomized, open-label phase II...
5.
Tesileanu C, Sanson M, Wick W, Brandes A, Clement P, Erridge S, et al.
Clin Cancer Res
. 2022 Mar;
28(12):2527-2535.
PMID: 35275197
Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular...
6.
van den Bent M, Tesileanu C, Wick W, Sanson M, Brandes A, Clement P, et al.
Lancet Oncol
. 2021 May;
22(6):813-823.
PMID: 34000245
Background: The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of...
7.
Tesileanu C, van den Bent M, Sanson M, Wick W, Brandes A, Clement P, et al.
Neuro Oncol
. 2021 Apr;
23(9):1547-1559.
PMID: 33914057
Background: Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related to outcome in IDH1/2mt...
8.
Tesileanu C, Vallentgoed W, Sanson M, Taal W, Clement P, Wick W, et al.
Acta Neuropathol
. 2021 Mar;
141(6):945-957.
PMID: 33740099
Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that...
9.
Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R, et al.
Cancer Treat Rev
. 2020 Apr;
86:102017.
PMID: 32335505
When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking...
10.
Labreche K, Daniau M, Sud A, Law P, Royer-Perron L, Holroyd A, et al.
Neuro Oncol
. 2019 May;
21(8):1039-1048.
PMID: 31102405
Background: Primary central nervous system lymphoma (PCNSL) is a rare form of extra-nodal non-Hodgkin lymphoma. PCNSL is a distinct subtype of non-Hodgkin lymphoma, with over 95% of tumors belonging to...